Deinove

Investment summary

Deinove is running a Phase II study with the novel quinolonyl-oxazolidinone class antibiotic DNV3837 for moderate to severe C. diff infections. This is an open-label study that will be conducted in two parts in 15 centres in the US. Part two of the study will be randomised in up to 30 patients and will include efficacy endpoints. The company also reported multiple developments in its bioactives portfolio. The most recent development was the launch of Luminity, which is a concentrate of neurosporene, an extremely rare carotenoid that contributes to skin vitality and a beautiful complexion. As a metabolic intermediate of the formation of lycopene from phytoene, neurosporene is a carotenoid rarely found in nature, which is now commercially accessible and patent protected. Deinove confirmed Luminity’s effects in in vitro, ex vivo and clinical studies. In November, Deinove signed an evaluation and technology development programme with nutrition company DSM for a microbial strain identified in its Color-2B program; deal terms were not disclosed.